Back to top
more

BridgeBio Pharma (BBIO)

(Delayed Data from NSDQ)

$27.09 USD

27.09
1,733,139

+1.21 (4.68%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $27.28 +0.19 (0.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 15% (38 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study

by Zacks Equity Research

BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.

BridgeBio Pharma (BBIO) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

BridgeBio Pharma (BBIO) closed the most recent trading day at $14.65, moving -1.81% from the previous trading session.

BridgeBio Pharma (BBIO) Moves 14.6% Higher: Will This Strength Last?

by Zacks Equity Research

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Biotech Stock Roundup: Regulatory Updates From NVAX, BBIO Down on Drug Failure & More

by Zacks Equity Research

Regulatory and other pipeline updates from NVAX and BBIO are among a few key highlights from the biotech sector during the past week.

Company News for Dec 28, 2021

by Zacks Equity Research

Companies in The News Are: GDDY,BBIO,UAL,MBOTSYK

BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure

by Zacks Equity Research

BridgeBio's (BBIO) acoramidis fails to meet the primary endpoint of a six-minute walk test in cardiomyopathy patients. However, secondary data demonstrate a favorable trend. The study continues.

Implied Volatility Surging for BridgeBio (BBIO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to BridgeBio (BBIO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in BridgeBio (BBIO) Stock?

by Zacks Equity Research

Investors need to pay close attention to BridgeBio (BBIO) stock based on the movements in the options market lately.

BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -16.48% and -87.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 29.03% and 7.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -35.63% and -95.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for BridgeBio Pharma (BBIO) This Earnings Season?

by Zacks Equity Research

BridgeBio Pharma (BBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -17.44% and -99.21%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.03% and -52.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: BridgeBio Pharma (BBIO) Q3 Earnings Expected to Decline

by Zacks Equity Research

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alexion Plans to Raise 2020 Sales View, Buy Back $3B Shares

by Zacks Equity Research

Alexion (ALXN) announces plans to increase its 2020 sales guidance by more than $200 million and buy back $3 billion of stock.

Why BridgeBio (BBIO) Stock Might be a Great Pick

by Zacks Equity Research

BridgeBio (BBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%

by Zacks Equity Research

BridgeBio Pharma (BBIO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan

by Zacks Equity Research

Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.